Login
$STXS
$0.80 -$0.00 (0.34%) Pre-market

$STXS 8-K SEC Filings

Filed On Filing
10 Nov 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more

St. Louis, November 10, 2026 (Globe Newswire) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates and financial results for the th...

11 Aug 2026 8-K: Results of Operations and Financial Condition

Robotic catheter revenue surpasses $1M in the quarter, growing 270% sequentially

16 Jul 2026 8-K: Other Events

We may be unable to successfully integrate Robocath into our business and may fail to realize any or all of the anticipated benefits of the acquisition, or those benefits may take longer to realize than expected.

09 Jul 2026 8-K: Unregistered Sales of Equity Securities; Regulation FD Disclosure +1 more

St. Louis, USA & Rouen, France, July 9, 2026 (Globe Newswire) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has completed its previo...

15 May 2026 8-K: Submission of Matters to a Vote of Security Holders

On May 14, 2026, the Company held its Annual Meeting of Shareholders. A total of 97,477,538 shares of common stock were outstanding and entitled to vote, and the holders of Series A Convertible Preferred Stock were entitled to an aggrega...

12 May 2026 8-K: Results of Operations and Financial Condition

Proprietary robotically-navigated MAGiC catheter received U.S. FDA approval in January and is now being utilized at multiple sites across the United States as well as Europe

15 Apr 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

On April 14, 2026, Stereotaxis, Inc. (“Stereotaxis” or the “Company”) entered into a Share Sale Agreement with Robocath, a French société par actions simplifiée, (“Robocath”), the shareholders of Robocath party thereto (the “Sellers”) an...

09 Mar 2026 8-K: Results of Operations and Financial Condition

St. Louis, MO, March 9, 2026 (Globe Newswire) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full...

12 Nov 2025 8-K: Results of Operations and Financial Condition

St. Louis, MO, November 11, 2025 (Globe Newswire) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended...

29 Aug 2025 8-K: Entry into a Material Definitive Agreement

Stereotaxis, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Roth Capital Partners, LLC (the “Agent”), as follows:

07 Aug 2025 8-K: Results of Operations and Financial Condition

St. Louis, MO, August 7, 2025 (Globe Newswire) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended J...

17 Jul 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of July 17, 2025, by and between Stereotaxis, Inc., a Delaware corporation (the “Company”), and each of the investors executing the signature pages attached hereto (each, an “Inv...

17 Jul 2025 8-K: Results of Operations and Financial Condition; Other Events

The Company expects to report revenue for 2025 second quarter in the range of $8.5 million to $8.8 million, reflecting growth of approximately 15% sequentially over its 2025 first quarter and 90% on a year-over-year basis compared to the...

19 May 2025 8-K: Submission of Matters to a Vote of Security Holders

On May 15, 2025, the Company held its Annual Meeting of Shareholders. A total of 85,979,662 shares of common stock were outstanding and entitled to vote, and the holders of Series A Convertible Preferred Stock were entitled to an aggrega...

12 May 2025 8-K: Results of Operations and Financial Condition

St. Louis, MO, May 12, 2025 (Globe Newswire) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended Marc...

03 Mar 2025 8-K: Results of Operations and Financial Condition

St. Louis, MO, March 3, 2025 (Globe Newswire) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full...

12 Nov 2024 8-K: Results of Operations and Financial Condition

St. Louis, Nov. 11, 2024 (Globe Newswire) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended Septemb...

12 Aug 2024 8-K: Results of Operations and Financial Condition

ST. LOUIS, August 12, 2024 (GLOBE NEWSWIRE) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June...

02 Aug 2024 8-K: Unregistered Sales of Equity Securities; Other Events

The disclosures set forth in Item 8.01 below with respect to the issuance of the Upfront Stock Consideration are incorporated by reference into this Item 3.02.

18 Jul 2024 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

St. Louis, July 18, 2024 (GLOBE NEWSWIRE) – Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the appointment of Nachum “Homi” Shamir to its Board of Directors.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support